Nanovibronix, INC 8-K filings
NanoVibronix CEO, Brian Murphy, presented company materials at the Annual Meeting of Stockholders on December 19, 2024.
NanoVibronix has renewed its exclusive distribution agreement with Ultra Pain Products for another five years, securing a minimum purchase commitment of $12 million for its PainShield product.
NanoVibronix has received a second deficiency notice from Nasdaq for failing to meet the minimum stockholders' equity requirement, adding to existing concerns about its share price.
NanoVibronix has received a delisting notice from Nasdaq after failing to maintain a minimum share price of $1.00, and plans to request a hearing to appeal the decision.
NanoVibronix has announced the date for its 2024 Annual Meeting of Stockholders and established deadlines for shareholder proposals and director nominations.
NanoVibronix has entered into new employment agreements with its CEO, Brian Murphy, and CFO, Stephen Brown, extending their roles through August 31, 2025.
NanoVibronix announced record first-quarter revenue of $921,000 and highlighted progress in sales, product development, and strategic partnerships.
NanoVibronix has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.
NanoVibronix achieved its highest ever quarterly revenue in Q4 2023 and is focused on expanding distribution and product development.
NanoVibronix has partnered with Veranex to enhance its PainShield and UroShield products, focusing on improved functionality and reduced costs.
NanoVibronix has cancelled its Special Meeting of Shareholders previously scheduled for January 25, 2024.